TY  - EJOU
AU  - LOGOTHETIS, CONSTANTINE N. 
AU  - HORVAT, NATHAN P. 
AU  - KURIAN, TONY 
AU  - BELLO, CELESTE 
AU  - CHAVEZ, JULIO 
AU  - ISENALUMHE, LEIDY 
AU  - SHAH, BIJAL 
AU  - SOKOL, LUBOMIR 
AU  - SAEED, HAYDER 
AU  - PINILLA, JAVIER 
AU  - GABALLA, SAMEH 

TI  - Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience
T2  - Oncology Research

PY  - 2024
VL  - 32
IS  - 6
SN  - 1555-3906

AB  - Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases of marginal zone lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin’s lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving frontline BR. Twenty-five patients were included with a median age of 69 years (40–81). Five (20.0%) patients had stage I/II disease, and 20 (80.0%) had stage III/IV disease. The median number of cycles was 6.0 (3.0–6.0). Maintenance rituximab was administered to 10 (41.7%) individuals. Overall response rate (ORR) was 100.0% (60.0% complete response, 40.0% partial response). Medians of overall survival and progression-free survival were not reached. The estimated 2-year progression-free survival was 85.2% and overall survival was 100.0%. Four (16.6%) patients had infections related to treatment; 3 (12.0%) transformed to diffuse large B-cell lymphoma; 5 (20.8%) had a relapse or progression of EMZL; and 3 (12.0%) died unrelated to BR. BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.
KW  - Extranodal marginal zone lymphoma; Bendamustine; Rituximab; Front-line therapy

DO  - 10.32604/or.2024.046885